Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

New Generation Drug Discovery Software Enters Market

Released on = October 25, 2005, 11:06 am

Press Release Author = Quantum Pharmaceuticals

Industry = Biotech

Press Release Summary = Quantum Pharmaceuticals is issuing its first commercial release of research software that is expected to speed up pharma R&D radically and irrevocably change the drug discovery software market.

Press Release Body = Quantum 3.1 is a suite of drug discovery software for Linux and Windows designed to enhance stages of drug discovery workflows, such as target identification, drug hit identification, lead identification and lead optimization.

The Quantum software was developed using a new paradigm in molecular modeling – applying quantum and molecular physics instead of statistical scoring-function-like and QSAR-like methods.

The key benefit of Quantum is the outstanding precision of molecular modeling and calculations. Using Quantum 3.1, researchers can calculate the IC50 of protein-ligand and protein-protein complexes, perform ligand docking, perform virtual screening of small-molecule libraries, analyze large-scale protein movements, perform de novo drug design and calculate the solvation energy and solubility.

Quantum 3.1 also helps detect potential moderate-to-serious adverse activity, additional unexpected activity and broad relative selectivity for a library of compounds by screening them against several hundred ADME/TOX-associated proteins.

The Mutagenesis module of Quantum 3.1 provides an interface for changing the protein sequence at specific sites through alterations to its amino acids and predicts changes in the bioactivity after mutations.

The Quantum software was successfully applied in different in-house and collaborative drug discovery projects of Quantum Pharmaceuticals. As a result of applying Quantum software, the range of the novel chemical inhibitor classes were discovered for disease targets, including HIV-I integrase (AIDS), Beta-Secretase
(Alzheimer’s disease), Human Neutrophil Elastase (CF, COPD), FtsZ (TB) and some others. Quantum technology has demonstrated itself to be very effective in creating revolutionary new medicine, and it has demonstrated its ability to discover new classes of inhibitors.

The free demo version of Quantum 3.1 can be downloaded from Quantum's web site.

About Quantum Pharmaceuticals

Quantum Pharmaceuticals, the leader in drug discovery technology, serves the life sciences industry and research community by providing top-of-the-line drug discovery products and services.

Since 2002 Quantum Pharmaceuticals has been developing its superior proprietary computer-based molecular modeling technology. The Quantum technology includes the latest achievements in the fields of physics, mathematics and chemistry. It demonstrates outstanding speed and accuracy of affinity calculations using fast
quantum calculations which take into account the full flexibility of molecules, solvation effects and entropy contribution. This provides unprecedented possibilities for drug discovery.

The headquarters of Quantum Pharmaceuticals is in Moscow, and its worldwide distribution network is expanding.

www.q-pharm.com

Web Site = http://www.q-pharm.com

Contact Details = office@q-pharm.com
tel 70951529615

 


  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •